The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. It also explains how the Centers for Medicare & Medicaid Services will help ensure Medicare beneficiaries can access drugs at the negotiated prices from the first and second cycles when those prices become effective in 2026 and 2027, respectively. CMS in August announced lower prices for 10 drugs covered by Part D that were selected in the first round. AHA in July commented on the guidance for the program, expressing concern about CMS’ proposal to retrospectively effectuate access to the negotiated prices and its implications for the 340B program. AHA will share more information soon about specific implications of the final guidance for hospitals. 

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…